Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Qnovia

Request full access

Pharmaceutical company whose mission is to help save lives

West Hollywood, United StatesFounded 2018Biotech & Life Sciences

About Qnovia

Qnovia, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing inhaled therapeutics. Founded in 2018 by Mario Danek as Respira Technologies, the company rebranded to Qnovia in September 2022. Danek, an inventor with a background in company launches, hardware manufacturing, and FDA regulatory strategy, created the initial prototype for the company's core technology after identifying a gap in the market for more effective smoking cessation tools. The company, initially based in Los Angeles, later relocated its headquarters to Richmond, Virginia, to be closer to key partners.

The company's primary business is the development of drug-device combination products aimed at improving patient outcomes, with an initial focus on the multi-billion dollar nicotine replacement therapy (NRT) market. Qnovia is developing a prescription-based treatment for smokers who want to quit. The business model centers on gaining regulatory approval for its products and then commercializing them, targeting a patient population that has not seen significant treatment advancements in decades. Since its inception, the company has raised $50 million through several funding rounds, including a $17 million Series A in 2022 and a $16 million Series B in late 2024, with lead investors like Blue Ledge Capital, Evolution VC Partners, and Vice Ventures.

Qnovia's lead product is the RespiRx™, a portable, orientation-agnostic, vibrating mesh nebulizer. This device is designed for the deep lung delivery of pharmaceuticals. Its first application, QN-01, is a prescription nicotine inhaler intended as a smoking cessation therapy. Unlike existing NRTs such as patches or gums which deliver nicotine slowly, the RespiRx™ is engineered to provide rapid delivery upon inhalation, more effectively managing cravings and withdrawal symptoms. The system uses single-use, pre-filled cartridges, eliminating the need for cleaning and maintenance. It also features a digital display to track dosing in real-time, supporting a 12-week step-down program where the nicotine dose is gradually reduced. In October 2024, the FDA cleared Qnovia's Investigational New Drug (IND) application, allowing the company to begin Phase 1 clinical trials in the U.S. The company is simultaneously pursuing a Marketing Authorization Application (MAA) in the U.K. for an expedited path to revenue. Beyond NRT, Qnovia plans to leverage its platform for other therapeutic areas, including asthma, COPD, vaccine delivery, and pain management.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2018
Headquarters
West Hollywood, United States
Employees
13
Open positions
None listed
Dealroom signal
76.9/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Addiction, Hard Tech, DT and LS, science-based
Technology
Hardware
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Dec 2024 $16M $64M Vice Ventures · Blue Ledge Capital · Gaingels · Evolution VC Partners ↗
SERIES A✓Equity / VC Jun 2023 $2.9M $85M Blue Ledge Capital · Evolution VC Partners ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Qnovia website traffic

Latest recorded traffic for Qnovia is 130 monthly website visits, down 18.8% over the last three months. Qnovia's team grew 8.3% over the past year.

Latest monthly visits130 3-month web change-18.8% 1-year team growth+8.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Qnovia in the West Hollywood ecosystem

Live from Dealroom

The Qnovia office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Poseidon Asset Management
  • Sand Hill Angels
  • Gaingels
  • Vice Ventures
  • DG Ventures
  • Blue Ledge Capital
  • TL Capital
  • Evolution VC Partners
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States60%
🇬🇧 United Kingdom30%
🇸🇪 Sweden10%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Qnovia on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Qnovia’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.